Medicare Prescription Drug, Improvement, and Modernization Act
The Medicare Prescription Drug, Improvement, and Modernization Act,[1] also called the Medicare Modernization Act or MMA, is a federal law of the United States, enacted in 2003.[2] It produced the largest overhaul of Medicare in the public health program's 38-year history.
Long title
An act to amend title XVIII of the Social Security Act to provide for a voluntary prescription drug benefit under the medicare program and to strengthen and improve the medicare program, and for other purposes.
Medicare Modernization Act or MMA
The MMA was signed by President George W. Bush on December 8, 2003, after passing in Congress by a close margin.[3]
Health savings accounts[edit]
The MMA created a new Health Savings Account statute that replaced and expanded the previous Medical Savings Account law by expanding allowable contributions and employer participation.[4] After the first 10 years over 12 million Americans were enrolled in HSAs (AHIP;EBRI).[5][6]
Costs[edit]
Initially, the net cost of the program was projected at $400 billion for the ten-year period between 2004 and 2013. Administration official Thomas Scully instructed analyst Richard Foster not to tell Congress of Foster's finding that the cost would actually be over $500 billion. One month after passage, the administration estimated that the net cost of the program over the period between 2006 (the first year the program started paying benefits) and 2015 would be $534 billion.[19] As of February 2009, the projected net cost of the program over the 2006 to 2015 period was $549.2 billion.[20]
Bar to negotiation of prescription drug prices[edit]
After the enactment of Medicare Prescription Drug, Improvement, and Modernization Act in 2003, only insurance companies administering Medicare prescription drug program, not Medicare, had the legal right to negotiate drug prices directly with drug manufacturers. The Medicare Prescription Drug Act expressly prohibited Medicare from negotiating bulk prescription drug prices.[21] The "donut hole" provision of the Patient Protection and Affordable Care Act of 2010 was an attempt to correct the issue.[22] In 2022, the Inflation Reduction Act removed this ban and allowed Medicare to begin negotiating drug prices starting in 2026.[23]